P014 Melanoma
DESCRIPTION
Our understanding of melanoma biology, risk, and diagnosis continues to evolve rapidly. This session will cover topics ranging from the potential roles and innovation opportunities presented by melanoma public health, diagnostic technologies, genomics, and innovative surgical and medical approaches to melanoma.
LEARNING OBJECTIVES
Describe the latest technologies available for the diagnosis of melanoma.
Recognize optimal use of novel ancillary testing strategies in melanoma diagnosis, including genetic testing.
Critically evaluate innovative surgical and medical oncology approaches to melanoma.
SCHEDULE
2:00 PM
Updates in Population Screening and Overdiagnosis
Rebecca I Hartman, MD, MPH, FAAD
2:15 PM
Total Body Photography - Current Practices and Future Applications
Andrew Charles Walls, MD, FAAD
2:30 PM
Updates in AI and Melanoma
Shannon Wongvibulsin, MD, PhD
2:45 PM
Q&A: Drs. Hartman, Walls, Wongvibulsin
3:00 PM
Updates in Germline Genetics in Melanoma
Joshua Arbesman, MD, FAAD
3:15 PM
Melanoma Dermatopathology Updates
Emily Y. Chu, MD, PhD, FAAD
3:30 PM
Updates in Gene Expression Profile Testing and Melanoma
Hensin Tsao, MD, PhD, FAAD
3:45 PM
Q&A: Drs. Arbesman, Chu, and Tsao
4:00 PM
Updates in Mohs for Melanoma
Daniel Lewis, MD, FAAD
4:15 PM
Updates in Systemic Therapies for Melanoma
Justine Cohen, DO
4:30 PM
Updates in Cutaneous Toxicities and Melanoma
Cuong Nguyen, MD, FAAD
4:45 PM
Q&A: Drs. Lewis, Cohen, Nguyen
SPEAKERS
Joshua Arbesman, MD, FAAD
Cleveland Clinic
Emily Y. Chu, MD, PhD, FAAD
Justine Cohen, DO
Dana-Farber Cancer Institute
Rebecca I Hartman, MD, MPH, FAAD
Daniel Lewis, MD, FAAD
Cuong Nguyen, MD, FAAD
Hensin Tsao, MD, PhD, FAAD
Andrew Charles Walls, MD, FAAD
Shannon Wongvibulsin, MD, PhD
UCLA
HANDOUTS
SPEAKER DISCLOSURES
Joshua Arbesman, MD, FAAD
Castle Biosciences, Inc – Investigator(Grants/Research Funding); Curio Science LLC – Speaker/Faculty Education(Honoraria); Disc Medicine – Advisory Board(Honoraria); OpenEvidence – Consultant (1099 relationship)(Honoraria); Sanotize – Stockholder Private Company(Stock); Variant Bio – Investigator(Grants/Research Funding);
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Justine Cohen, DO
Bristol-Myers Squibb – Advisory Board(Honoraria); Replimune – Advisory Board(Honoraria);
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees); Zura Bio – Data Safety Monitoring Board(Fees);
Daniel Lewis, MD, FAAD
No financial relationships exist with ineligible companies.
Cuong Nguyen, MD, FAAD
No financial relationships exist with ineligible companies.
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);
Andrew Charles Walls, MD, FAAD
No financial relationships exist with ineligible companies.
Shannon Wongvibulsin, MD, PhD
Sanofi/Regeneron – Advisory Board(Honoraria); VisualDx – Consultant (1099 relationship)(Honoraria);